Other languages H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-12 am EDT			5-day change	1st Jan Change
40.06 ^DKK	-1.43%		+1.52%	+22.28%

Jun. 26	Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	MT
Jun. 25	US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application	Jun. 25
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment	Jun. 25
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	Jun. 25
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial	Jun. 19
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	Jun. 03
H LUNDBECK : Q1 beat adds momentum to the recent share price rally	May. 15
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	May. 15
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	May. 13
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	May. 13
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	Mar. 27
H. Lundbeck A/S Announces Management Appointments	Mar. 20
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	Mar. 20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	Mar. 15
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	Mar. 15
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	Feb. 23
H. Lundbeck A/S Announces Changes to Executive Management	Feb. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 12:20 pm EDT